Biotronik touts 1st-in-human data for its entry into the transcatheter aortic valve implant market, saying the device passed its 30-day safety endpoint.
Biotronik today said its entry into a hot replacement heart valve market passed the safety endpoint of a 1st-in-human trial.
The German medical device giant said the Biovalve trial of its transcatheter aortic valve implant established the device's early safety at 30 days.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1zW4FIj
Cap comentari:
Publica un comentari a l'entrada